Pacira Pharma (PCRX) Misses Q2 EPS by 1c

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.23, $0.01 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $62.97 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• New leader board: Citi refreshes AI compute semiconductor picks
• FTAI Infrastructure buys Tidewater Logistics for $45 million
• BMO Capital Upgrades Casey's General Stores (CASY) to Outperform, 'Opportunity Knocks'